Last updated on February 2018

Biological Therapy in Treating Patients at High-Risk or With Lymphoma Lymphoproliferative Disease or Malignancies


Brief description of study

The purpose of this phase I/II trial is to study the side effects and best dose of biological therapy to treat patients at high-risk or with Epstein-Barr virus-associated lymphoma or lymphoproliferative disease.

Clinical Study Identifier: NCT00002663

Contact Investigators or Research Sites near you

Start Over

Susan Prockop, MD

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »